OBJECTIVES: The study aims to determine the impact of payer status on the likelihood of receiving definitive treatment for invasive cervical cancer at a tertiary medical center. METHODS: All consecutive patients presenting to Johns Hopkins Hospital with a diagnosis of invasive cervical cancer between 1/1/95-12/31/08 were retrospectively identified from the tumor registry. Demographic and clinical information were abstracted from the medical record. Payer status was categorized as private, public, no insurance, or unknown. Treatment was defined as surgery, chemo-radiation, chemotherapy, radiation, or no definitive therapy. The likelihood of receiving no definitive therapy was analyzed using Pearson chi-square analysis, univariate and multivariate models. RESULTS: A total of 306 patients were identified. Median age was 47 and 60% of patients had early stage disease at diagnosis (stages IA-IIA). Fifty-six percent of the cohort had private insurance, 34% had public insurance, and 6% had no insurance. Having no insurance was the single most significant risk factor associated with receiving no standard therapy. While 7% of privately insured and 4% of publicly insured patients did not receive definitive therapy, 16% of uninsured patients did not receive definitive treatment. In multivariate analysis controlling for age, race, stage, histology, and comorbidities, uninsured payer status was a significant and independent predictor of receiving no definitive treatment (OR 8.01, CI 1.265-50.694, p=0.027) than patients with public insurance. CONCLUSIONS: In this study, uninsured payer status was significantly associated with a higher likelihood of not receiving standard therapy for cervical cancer. Additional studies are warranted to characterize specific barriers to care for this at-risk population. Published by Elsevier Inc.
OBJECTIVES: The study aims to determine the impact of payer status on the likelihood of receiving definitive treatment for invasive cervical cancer at a tertiary medical center. METHODS: All consecutive patients presenting to Johns Hopkins Hospital with a diagnosis of invasive cervical cancer between 1/1/95-12/31/08 were retrospectively identified from the tumor registry. Demographic and clinical information were abstracted from the medical record. Payer status was categorized as private, public, no insurance, or unknown. Treatment was defined as surgery, chemo-radiation, chemotherapy, radiation, or no definitive therapy. The likelihood of receiving no definitive therapy was analyzed using Pearson chi-square analysis, univariate and multivariate models. RESULTS: A total of 306 patients were identified. Median age was 47 and 60% of patients had early stage disease at diagnosis (stages IA-IIA). Fifty-six percent of the cohort had private insurance, 34% had public insurance, and 6% had no insurance. Having no insurance was the single most significant risk factor associated with receiving no standard therapy. While 7% of privately insured and 4% of publicly insured patients did not receive definitive therapy, 16% of uninsured patients did not receive definitive treatment. In multivariate analysis controlling for age, race, stage, histology, and comorbidities, uninsured payer status was a significant and independent predictor of receiving no definitive treatment (OR 8.01, CI 1.265-50.694, p=0.027) than patients with public insurance. CONCLUSIONS: In this study, uninsured payer status was significantly associated with a higher likelihood of not receiving standard therapy for cervical cancer. Additional studies are warranted to characterize specific barriers to care for this at-risk population. Published by Elsevier Inc.
Authors: Linda C Harlan; Amanda L Greene; Limin X Clegg; Margaret Mooney; Jennifer L Stevens; Martin L Brown Journal: J Clin Oncol Date: 2005-11-21 Impact factor: 44.544
Authors: J Hsia; E Kemper; C Kiefe; J Zapka; S Sofaer; M Pettinger; D Bowen; M Limacher; L Lillington; E Mason Journal: Prev Med Date: 2000-09 Impact factor: 4.018
Authors: Cynthia D O'Malley; Sarah J Shema; Lisa S Clarke; Christina A Clarke; Carin I Perkins Journal: Am J Public Health Date: 2006-10-31 Impact factor: 9.308
Authors: Shannon N Westin; Dan Bustillos; Jacalyn B Gano; Margaret M Fields; Ann L Coker; Charlotte C Sun; Lois M Ramondetta Journal: Obstet Gynecol Date: 2008-03 Impact factor: 7.661
Authors: Thomas Churilla; Brian Egleston; Yanqun Dong; Talha Shaikh; Colin Murphy; Gina Mantia-Smaldone; Christina Chu; Stephen Rubin; Penny Anderson Journal: Gynecol Oncol Date: 2016-03-25 Impact factor: 5.482
Authors: Anna Louise Beavis; Awa Sanneh; Rebecca L Stone; Margaret Vitale; Kimberly Levinson; Anne F Rositch; Amanda Nickles Fader; Kristin Topel; Ashley Abing; Stephanie L Wethington Journal: Am J Obstet Gynecol Date: 2020-05-17 Impact factor: 8.661
Authors: Wonsuk Yoo; Sangmi Kim; Warner K Huh; Sarah Dilley; Steven S Coughlin; Edward E Partridge; Yunmi Chung; Vivian Dicks; Jae-Kwan Lee; Sejong Bae Journal: PLoS One Date: 2017-02-24 Impact factor: 3.240